Tuesday, October 13, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 5, 2026

26 Top Dividend Stocks to Buy and Hold in 2026

View original at finance.yahoo.com
26 Top Dividend Stocks to Buy and Hold in 2026 Key Points Top dividend stocks for 2026 include many that offer ultra-high yields of over 6%…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Top dividend stocks for 2026 include many that offer ultra-high yields of over 6%

    80% confidence

  • Alphabet checks off nearly every box in the AI arena, with a top-three cloud platform, a leading large language model (LLM), and AI chips that are gaining market momentum

    80% confidence

  • UnitedHealth Group's stock could bounce back in 2026 after struggling in 2025

    80% confidence

  • Stock Advisor's total average return is 966% compared to 194% for the S&P 500

    80% confidence

  • Enbridge is the most intriguing stock in the energy group

    80% confidence

  • Identified 10 best stocks for investors to buy now, and Alphabet wasn't one of them

    80% confidence

  • AbbVie has roared back after facing patent cliff with Humira and is one of the best healthcare stocks on the market for income investors

    80% confidence

Data points we hold from this source

AbbVie Inc. · market cap405 billion_USD
The Coca-Cola Company · market cap301 billion_USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,372 source documents archived
Query this data → isubstrate.com